News

Partners since 2019, Institut Curie and Biomunex announce a new stage in their strategic research collaboration. Already co-inventor and 50% co-owner of this approach, Biomunex has signed an exclusive licensing agreement with Institut Curie for the clinical development of a new class of antibodies, capable of specifically targeting, engaging and redirecting MAIT cells to destroy cancer cells. A further step towards new, safer and more effective cutting-edge immunotherapies for the benefit of patients.

Neuroscientists and neurosurgeons from EPFL/CHUV/UNIL and CEA/FDD Clinatec/CHUGA/UGA report in the journal Nature that they have re-established the communication between the brain and spinal cord with a wireless digital bridge, allowing a paralyzed person to walk again naturally.

For the first time worldwide, an artificial intelligence (AI) tool is clinically validated for breast cancer diagnosis. Institut Curie and Ibex Medical Analytics, a pioneer in AI-based cancer diagnosis, demonstrate the performance, reliability and clinical application of an AI algorithm for breast biopsy diagnosis. These results were just published in the journal npj breast cancer.

Valeo and the Carnot Institute CEA LETI signed an agreement to collaborate on the next generations of power electronics, which are at the heart of the challenges facing tomorrow's electric mobility.

The two organizations will share a joint roadmap to create long-term disruptive technologies in France and Europe. The first scientific and technological areas of focus include virtual twin experiences in health and cybersecurity. The alliance aims to support French and European ecosystems in these domains and the digital trust dynamic. Alliance builds on the existing 20-year collaboration between the two organizations that has already helped advance science and innovation in digital technology.

AVATAR MEDICAL, spin-off from Carnot Curie Cancer Institute and Carnot Pasteur MS Institute, announces a €1.2 million fundraising for its virtual reality solution that aims to radically change the way surgeons access, interpret and act on clinical data contained in medical images.

IQVIA, world leader in the healthcare data market, and the CALYM Carnot Institute, Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field, have entered into a strategic partnership around a hematology database, the HemSys software. As part of this exclusive partnership, IQVIA is making its expertise and network available to CALYM, in the valorization of health data for research purposes and access to the market for therapeutic innovations.

For this 100% digital version, the CEA is supporting 3 spin off start-ups from its laboratories that have developed technological solutions in response to three major societal challenges: 

• The energy transition, with Wise-Integration, which will present the world's smallest charger for electric bicycles,

• The digital transition with Alkalee, which has developed a software suite equipped to bring agility and openness to the vehicles of tomorrow,

• And the health of the future, with iUMTEK for rapid quantitative and qualitative diagnosis of air pollution

Institut Curie (Curie Cancer Carnot Institute) and Google initiate a joint artificial intelligence research program to develop and implement deep learning methods for the analysis of complex single-cell transcriptomic and epigenetics data. Obtained from mouse samples and cell lines, these valuable data sets will be used to develop new deep-learning algorithms. In the long term, this research project could help characterize the heterogeneity of tumors and predict resistance to treatment.

Institut Curie (Curie Cancer Carnot Insitute) and Ibex Medical Analytics, a pioneer in artificial intelligence based cancer diagnostics, announce a research partnership aimed at improving diagnosis of breast cancer with Artificial Intelligence

Owkin, a startup that deploys AI and Federated Learning technologies to augment medical research and enable scientific discoveries, announces a collaboration with Lymphoma research consortium Institut Carnot CALYM. This engagement was formed to leverage high-quality datasets from LYSARC, member of Institut Carnot CALYM, as well as Owkin’s pioneering technologies and research platform, to advance clinical research and drug development for the benefit of patients.

Each year, we host Leti Innovation Days (LIDs) to stimulate creativity and innovation in the semiconductor field. LIDs is a special moment where we, together, can imagine the next technologies that will have a strong impact in this industry. 

LIDs 2020 were initially planned June 24-26, but due to the global pandemic situation, we have decided to reschedule our Leti Innovations Days and workshops during Oct. 12-16, 2020 in Grenoble (France). We hope this will enable the attendees to find a source of interest in the quality of the agenda and a source of enthusiasm from the multiple discussions. The theme for LIDs 2020 is "New Turns in Innovation to Embrace the World"

You will learn what's coming to the market in the next 10 years at Leti Innovation Days (LID), October 12-16 in Grenoble.
LID are hosted by CEA LETI, a world-leading technology research institute that is performing pioneering R&D in micro- and nanotechnologies.